Sanara MedTech (SMTI) director granted 4,616 restricted stock shares under 2024 plan
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Ortwein Sara N reported acquisition or exercise transactions in this Form 4 filing.
Sanara MedTech Inc. director Sara N. Ortwein received a grant of 4,616 shares of common stock as restricted stock under the company’s 2024 Omnibus Long-Term Incentive Plan. These shares were awarded at no cash cost and increase her direct holdings to 25,415 shares.
The restricted stock will vest on the earlier of the company’s 2027 annual shareholder meeting or June 4, 2027, as long as she continues providing specified services to Sanara MedTech through that date. This filing reflects a compensation-related equity award rather than an open-market share purchase or sale.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Ortwein Sara N
Role
null
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 4,616 | $0.00 | -- |
Holdings After Transaction:
Common Stock — 25,415 shares (Direct, null)
Footnotes (1)
- [object Object]
Key Figures
Restricted stock grant: 4,616 shares
Price per share for grant: $0.0000 per share
Total shares after grant: 25,415 shares
+2 more
5 metrics
Restricted stock grant
4,616 shares
Common Stock award on June 4, 2026
Price per share for grant
$0.0000 per share
Reported grant price (compensation award)
Total shares after grant
25,415 shares
Direct holdings following the transaction
Vesting outside date
June 4, 2027
Latest vesting date for restricted stock
Vesting alternative event
2027 annual shareholder meeting
Earlier vesting trigger if before June 4, 2027
Key Terms
restricted stock, 2024 Omnibus Long-Term Incentive Plan, annual shareholder meeting, vest
4 terms
restricted stock financial
"Represents shares of restricted stock granted by Sanara MedTech Inc."
Shares granted to an individual that carry limits on transfer or sale until certain conditions are met, such as staying with the company for a set time or hitting performance targets. Think of them as a locked gift that gradually opens; for investors they matter because they affect how many shares may enter the market later, signal management incentives and potential dilution, and reveal confidence in future company performance.
2024 Omnibus Long-Term Incentive Plan financial
"pursuant to the Sanara MedTech Inc. 2024 Omnibus Long-Term Incentive Plan."
vest financial
"The restricted stock will vest on the earlier of"
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
FAQ
What insider transaction did Sanara MedTech (SMTI) report for Sara N. Ortwein?
Sanara MedTech reported that director Sara N. Ortwein received a grant of 4,616 shares of restricted common stock. The award was part of the 2024 Omnibus Long-Term Incentive Plan and did not involve an open-market purchase or sale.
Was cash paid for the Sanara MedTech (SMTI) restricted stock granted to Sara N. Ortwein?
No cash was paid for this award. The 4,616 restricted shares were granted at a reported price per share of $0.0000, reflecting a compensation-related equity grant rather than a purchase in the open market.
What plan governs the restricted stock grant to Sara N. Ortwein at Sanara MedTech (SMTI)?
The restricted stock grant was issued under the Sanara MedTech Inc. 2024 Omnibus Long-Term Incentive Plan. This plan authorizes equity-based compensation awards, including restricted stock, to directors and other service providers of the company.